# US 2024/0390330 A1 · Alpha-2-adrenergic receptor agonists for reducing redness and increasing whiteness in eyes and other ophthalmic purposes

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0390330 A1
- Document ID: US20240390330A1
- Status: Published application
- Kind: A1
- Application number: 18/434,505
- Filed: 2024-02-06
- Published: 2024-11-28
- Earliest claimed: 2020-02-20
- Assignees: Allergan, Inc.
- Applicants: Allergan, Inc.
- Inventors: Mohammed Dibas
- Web page: https://patentgrep.com/patent/US20240390330A1

## CPC

- A61K 31/4184: condensed with carbocyclic rings, e.g. benzimidazoles
- A61K 9/0048: {Eye, e.g. artificial tears}
- A61K 9/08: Solutions {(composition of solutions A61K47/00)}
- A61P 27/00: Drugs for disorders of the senses
- A61P 27/02: Ophthalmic agents
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The disclosure provides, inter alia, methods of reducing eye redness and/or increasing eye whiteness using alpha-2-adrenergic receptor agonists.

## Claims

### Claim 1

A method for reducing redness of an eye or increasing whiteness of an eye in an individual in need thereof, the method comprising administering to the individual a therapeutically effective amount of a compound of Formula I:
or a pharmaceutically acceptable salt thereof.

### Claim 2 (depends on 1)

The method of claim 1, wherein the method is for reducing redness of the eye.

### Claim 3 (depends on 2)

The method of claim 2, wherein the method is for reducing redness of the eye caused by minor eye irritations.

### Claim 4 (depends on 2)

The method of claim 2, wherein the method is for reducing redness of the eye due to dilation of vessels of the conjunctiva, the episclera, the sclera, or a combination of two or more thereof.

### Claim 5 (depends on 2)

The method of claim 2, wherein the method is for reducing chronic redness of the eye.

### Claim 6 (depends on 1)

The method of claim 1, wherein the method is for increasing whiteness of the eye.

### Claim 7 (depends on 6)

The method of claim 6, wherein the individual does not have an eye pathology.

### Claim 8 (depends on 1)

The method of claim 1, wherein the method is for reducing redness of the eye caused by laser-assisted in situ keratomileusis eye surgery.

### Claim 9 (depends on 1)

The method of claim 1, wherein the method reduces redness of the eye or increases whiteness of the eye within 5 seconds to 1 minute of administration.

### Claim at position 10

-12. (canceled)

### Claim 13 (depends on 1)

The method of claim 1, wherein the method reduces redness of the eye or increases whiteness of the eye for at least 8 hours, for at least 9 hours, for at least 10 hours, for at least 12 hours, or for at least 24 hours after administration.

### Claim at position 12

-17. (canceled)

### Claim 18 (depends on 1)

The method of claim 1, wherein the compound of Formula I or the pharmaceutically acceptable salt thereof is administered to one eye of the individual or to both eyes of the individual.

### Claim 19 (depends on 1)

The method of claim 1, comprising topically administering to the eye of the individual the therapeutically effective amount of the compound of Formula I or the pharmaceutically acceptable salt thereof.

### Claim 20 (depends on 1)

The method of claim 1, wherein the compound of Formula I or the pharmaceutically acceptable salt thereof is administered to the individual as a pharmaceutical composition comprising the therapeutically effective amount of the compound of Formula I or the pharmaceutically acceptable salt thereof and a pharmaceutically acceptable excipient.

### Claim 21 (depends on 20)

The method of claim 20, wherein the pharmaceutical composition comprises the compound of Formula I or the pharmaceutically acceptable salt thereof in an amount of about 0.001% (w/v) to about 0.02% (w/v).

### Claim at position 17

-27. (canceled)

### Claim 28 (depends on 20)

The method of claim 20, wherein the pharmaceutical composition is a solution.

### Claim 29 (depends on 20)

The method of claim 20, wherein the pharmaceutical composition is a dispersion.

### Claim 30 (depends on 20)

The method of claim 20, comprising topically administering to the eye of the individual one drop of the pharmaceutical composition.

### Claim 31 (depends on 20)

The method of claim 20, comprising topically administering to the eye of the individual two drops of the pharmaceutical composition.

### Claim 32 (depends on 20)

The method of claim 20, wherein the pharmaceutical composition is an ocular implant, intracameral implant, intravitreal implant, sub-conjunctival implant, sub-Tenon's implant, punctum plug, canicular eluting implant, or ocular ring.

### Claim 33

(canceled)

### Claim 34 (depends on 20)

The method of claim 20, wherein the therapeutically effective amount of the compound of Formula (I) or the pharmaceutically acceptable salt thereof is an amount that is less than a therapeutically amount of brimonidine that is needed to reduce redness of the eye or to increase whiteness of the eye.
